Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to donor availability in elderly patients with myelodysplastic syndrome.
1. What are the major unmet needs in the treatment of myelodysplastic syndrome (MDS) in elderly patients? (0:10)
2. What is the rationale for induction therapy with 5-azacytidine prior to allogeneic hematopoietic stem cell transplantation (HSCT)? (0:58)
3. Could you tell us a little about the rationale for and design of the phase III study you are presenting at ASH? (2:08)
4. What were the findings of this study? (3:24)
5. What are the implications of these findings for the future treatment of elderly patients with MDS? (4:34)
Speaker disclosures: Nicolaus Kröger has nothing to declare in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, December 1–4, 2018.
Share this Video
Related Videos In Haematological Malignancies
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!